Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
9.22
-0.40 (-4.16%)
At close: Mar 13, 2025, 4:00 PM
9.32
+0.10 (1.06%)
After-hours: Mar 13, 2025, 7:56 PM EST
Intellia Therapeutics Revenue
In the year 2024, Intellia Therapeutics had annual revenue of $57.88M with 59.55% growth. Intellia Therapeutics had revenue of $12.87M in the quarter ending December 31, 2024, a decrease of -771.57%.
Revenue (ttm)
$57.88M
Revenue Growth
+59.55%
P/S Ratio
15.75
Revenue / Employee
$143,615
Employees
403
Market Cap
954.43M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 57.88M | 21.60M | 59.55% |
Dec 31, 2023 | 36.28M | -15.85M | -30.40% |
Dec 31, 2022 | 52.12M | 19.07M | 57.69% |
Dec 31, 2021 | 33.05M | -24.94M | -43.01% |
Dec 31, 2020 | 57.99M | 14.89M | 34.55% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
NTLA News
- 2 days ago - Intellia Therapeutics, Inc. (NTLA) Barclays 27th Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 3 days ago - Intellia Therapeutics, Inc. (NTLA) Leerink 2025 Global Biopharma Conference (Transcript) - Seeking Alpha
- 5 days ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - GlobeNewsWire
- 7 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - Accesswire
- 7 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit - NTLA - PRNewsWire
- 9 days ago - Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 11 days ago - Intellia Trades Lower After Q4 Results As Clinical Progress Fails To Impress - Seeking Alpha
- 14 days ago - Intellia Therapeutics, Inc. (NTLA) Q4 2024 Earnings Call Transcript - Seeking Alpha